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Abstract The clinically established proarrhythmic effect of
bradycardia and antiarrhythmic effect of lidocaine (10 μM)
were reproduced in hypokalaemic (3.0 mM K
+) Langendorff-
perfused murine hearts paced over a range (80–180 ms) of
baseline cycle lengths (BCLs). Action potential durations (at
90% repolarization, APD90s), transmural conduction times
and ventricular effective refractory periods (VERPs) were
then determined from monophasic action potential records
obtained during a programmed electrical stimulation proce-
dure in which extrasystolic stimuli were interposed following
regular stimuli at successively decreasing coupling intervals.
A novel graphical analysis of epicardial and endocardial,
local and transmural relationships between APD90,c o r r e c t e d
for transmural conduction time where appropriate, and
VERP yielded predictions in precise agreement with the
arrhythmogenic findings obtained over the entire range of
BCLs studied. Thus, in normokalaemic (5.2 mM K
+)h e a r t s
a statistical analysis confirmed that all four relationships
were described by straight lines of gradients not significantly
(P>0.05) different from unity that passed through the origin
and thus subtended constant critical angles, θ with the
abscissa (45.8°±0.9°, 46.6°±0.5°, 47.6°±0.5° and 44.9°±
0.8°, respectively). Hypokalaemia shifted all points to the left
of these reference lines, significantly (P<0.05) increasing θ
at BCLs of 80–120 ms where arrhythmic activity was not
observed (∼63°, ∼54°, ∼55° and ∼58°, respectively) and
further significantly (P<0.05) increasing θ at BCLs of 140–
180 mswhere arrhythmicactivitywas observed(∼68°,∼60°,
∼61° and ∼65°, respectively). In contrast, the antiarrhythmic
effectoflidocainetreatmentwasaccompaniedbyasignificant
(P<0.05) disruption of this linear relationship and decreases
in θ in both normokalaemic (∼40°, ∼33°, ∼39° and ∼41°,
respectively)andhypokalaemic(∼40°,∼44°, ∼50°and∼48°,
respectively) hearts. This extended a previous approach that
had correlated alterations in transmural repolarization gra-
dients with arrhythmogenicity in murine models of the
congenital long QT syndrome type 3 and hypokalaemia at a
single BCL. Thus, the analysis in terms of APD90 and
VERP provided a more sensitive indication of the effect of
lidocaine than one only considering transmural repolarization
gradients and may be particularly applicable in physiological
and pharmacological situations in which these parameters
diverge.
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Introduction
A dependence of arrhythmogenicity upon heart rate,
frequently quantified in terms of baseline cycle length
(BCL), is well established in a range of clinical and
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Cambridge CB2 1QW, UKexperimental situations. Thus, in hereditary arrhythmic
syndromes including the congenital long QT syndrome
type 3 (LQT3) [43, 55], the Brugada syndrome [1] and
catecholaminergic polymorphic ventricular tachycardia [33,
49] bradycardia is associated with the initiation of arrhyth-
mic activity, while rapid pacing is antiarrhythmic. In LQT3
this relationship is further associated with the exacerbation
of an already existent QT prolongation [30], reflecting
increased action potential duration [50]. Such clinical
observations have been replicated in animal models of
LQT3, which have additionally demonstrated abnormal
differences between epicardial and endocardial action
potential durations [6, 12, 51].
This relationship between arrhythmogenicity, BCL and
QT interval has also been observed in situations of acquired
electrocardiographic QT prolongation resulting from treat-
ment with drugs including antiarrhythmics [9, 36, 56, 57]
and macrolide antibiotics [26, 28], cardiac hypertrophy [50]
and metabolic abnormalities including hypokalaemia [10,
45]. Such phenomena have frequently been associated with
alterations in repolarizing K
+ currents influencing the time
course of action potential recovery [17, 54, 58]. In such
situations arrhythmic activity is suppressed by the com-
monly used class 1b antiarrhythmic agent lidocaine [10, 45].
The present study begins by demonstrating an increase
in the incidence of arrhythmic activity as BCL is increased
over a physiological range for the first time in hypokalae-
mic hearts of any species, directly reflecting clinical
observations [10, 45]. This is also the first time that such
a finding has been reported in murine hearts under any
conditions. It then uses an analysis of arrhythmogenicity
involving local and transmural relationships between the
recovery of membrane voltage and of excitability following
depolarization developed in a previous paper [37]a sa
platform for the investigation of this phenomenon. This
represents the first exploration of the effect of BCL on such
relationships in any experimental system, whether murine
or otherwise.
Furthermore, this study introduces novel graphical plots
representing local and transmural relationships between
action potential duration (quantified at 90% repolarization,
APD90) and ventricular effective refractory period (VERP)
able to display data obtained over a range of BCLs. These
are used to demonstrate for the first time that in the
normokalaemic case APD90 and VERP, and local and
transmural relationships between them, alter with BCL in a
manner that prevents arrhythmogenesis. In sharp contrast
this relationship is shown to break down in the hypokalae-
mic case, with APD90 exceeding VERP at long BCLs, in
association with arrhythmogenesis. Furthermore, treatment
with lidocaine is demonstrated to result in the breakdown of
this relationship with VERP exceeding APD90, in associa-
tion with an anti-arrhythmic effect. Finally, this analysis is
compared with a generalization of a previous analysis that
related arrhythmogenicity to changes in relationships
between the recovery of membrane voltage in the epicar-
dium and in the endocardium [17, 18, 27, 51, 52]. This
analysis is extended from a single BCLs to a range of BCLs
and displayed as a novel plot.
Materials and methods
Mice were housed at 21±1°C with 12 h light/dark cycles
and were fed sterile chow (RM3 Maintenance Diet, SDS,
Witham, Essex, UK) with free access to water. Wild-type
129 Sv mice aged 3–6 months were used in procedures, all
of which complied with UK Home Office regulations
(Animals (Scientific Procedures) Act 1986). All solutions
were based on bicarbonate-buffered Krebs–Henseleit solu-
tion (mM: NaCl 119, NaHCO3 25, KCl 4, KH2PO4 1.2,
MgCl2 1, CaCl2 1.8, glucose 10 and Na-pyruvate 2; pH
adjusted to 7.4) bubbled with 95% O2/5% CO2 (British
Oxygen Company, Manchester, U.K). Hypokalaemic
(3.0 mM K
+) solutions were prepared by reduction of KCl
content. Lidocaine-containing normokalaemic and hypoka-
laemic solutions were prepared by adding lidocaine (Sigma-
Aldrich, Poole, UK) to a final concentration of 10 μM.
A Langendorff perfusion protocol previously adapted for
murine hearts [2] was used. In brief, mice were killed by
cervical dislocation (Schedule 1: UK Animals [Scientific
Procedures] Act 1986). Hearts were then quickly excised
and placed in ice-cold bicarbonate-buffered Krebs–Hense-
leit solution. A short section of aorta was cannulated under
the surface of the solution and attached to a custom-made
21-gauge cannula filled with the same solution using an
aneurysm clip (Harvard Apparatus, Edenbridge, Kent, UK).
Fresh Krebs–Henseleit solution was then passed through
200- and 5-μm filters (Millipore, Watford, UK), warmed to
37°C using a water jacket and circulator (Techne model C-
85A, Cambridge, UK) and used for constant-flow retro-
grade perfusion at 2–2.5 ml/min via a peristaltic pump
(Watson–Marlow Bredel model 505S, Falmouth, Cornwall,
UK). Hearts were regarded as suitable for experimentation
if, on rewarming, they regained a healthy pink colour and
began to contract spontaneously.
Epicardial monophasic action potential (MAP) electro-
des (Hugo Sachs, Harvard Apparatus, UK) were placed
against the basal left ventricular epicardium. In addition,
small windows were created in the septum between the left
and right ventricles to allow access to the left ventricular
endocardium [4]. Custom-made endocardial MAP electro-
des comprising two twisted strands of high-purity Teflon-
coated 0.25 mm diameter silver wire (Advent Research
Materials, UK) were constructed. The Telflon coats were
removed from the distal 1 mm of the electrodes, which
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inserted and placed against the septal endocardial surface.
MAPs were then amplified, band-pass filtered (0.5 Hz to
1 kHz: Gould 2400S, Gould-Nicolet Technologies, Ilford,
Essex, UK) and digitised at a sampling frequency of 5 kHz
(micro1401, Cambridge Electronic Design, Cambridge,
UK). Analysis of MAPs was performed using Spike II
software (Cambridge Electronic Design, Cambridge, UK).
A bipolar platinum stimulating electrode (1 mm inter-
pole spacing) was placed against the basal right ventricular
epicardium. Square-wave stimuli (Grass S48 stimulator,
Grass-Telefactor, Slough, UK) of 2-ms duration and with
amplitudes of twice the diastolic threshold were initially
applied to hearts at a constant baseline cycle length of
125 ms for at least 10 min and until MAPs showed stable
baselines, rapid upstroke phases that reached consistent
amplitudes and smooth repolarization phases [11, 19].
Hearts were then exposed to test solutions for 20 min,
during which time stimulation was continued, before
subsequent recordings were made.
Action potential duration (at 90% repolarization, APD90)
was quantified during regular stimulation at baseline cycle
lengths (BCLs) varied in 5-ms increments between 80 and
180 ms. Hearts were subjected to an adapted form of an
extrasystolic stimulation procedure previously used to
assess arrhythmogenicity and refractoriness in both human
[42] and murine [15] studies of long QT syndrome,
described in detail later. This procedure was used to assess
arrhythmogenicity and determine ventricular effective re-
fractory periods (VERPs) at BCLs varied in 10-ms incre-
ments between 80 and 180 ms. The possibility that events
evoked by extrasystolic stimuli rather represented motion
artefacts was excluded by their being reproducible between
hearts and appearing identical in both electrodes.
All data are presented as means ± standard errors of the
means (SEM) and include both the number of repetitions
and the number of hearts. Comparisons were made using
analysis of variance other than where stated. A significance
threshold of P≤0.05 was applied in all cases.
Results
The initial experiments quantitatively assessed the effect of
steady-state baseline cycle length (BCL) on the inducibility
of arrhythmic activity in hearts exposed to normokalaemic
(5.2 mM K
+), hypokalaemic (3.0 mM K
+), normokalaemic
lidocaine-containing (10 μM) and hypokalaemic lidocaine-
containing (10 μM) test solutions. Hearts were first exposed
to the test solutions for 20 min, while stimulated at a BCL
of 125 ms to allow a steady state to be reached.
Arrhythmogenicity was then assessed during 1-h periods
of regular stimulation at BCLs of 80 and 180 ms. In
addition, arrhythmogenicity was studied using an extra-
systolic stimulation procedure previously established in
human long QT syndrome (LQTS) [42] and adapted for use
in murine models [15]. This involved a standardised
stimulation protocol consisting of regular (S1) stimulation
at BCLs of 80 and 180 ms, interrupted by extrasystolic (S2)
stimuli imposed following every eighth S1 stimulus. The
S1S2 interval was decremented in 1-ms steps with each
successive stimulus cycle from the BCL. This was
continued until the S2 stimulus either appeared to initiate
arrhythmic activity, confirmed by the persistence of
irregular waveforms on cessation of stimulation, or failed
to initiate a MAP, suggesting that the ventricular effective
refractory period (VERP) had been reached.
Arrhythmic activity occurs in hypokalaemic hearts paced
at long but not short baseline cycle lengths
While studies under normokalaemic conditions confirmed
an absence of arrhythmic activity at either BCL (0 out of
five hearts subjected to regular stimulation, 0 out of seven
hearts subjected to S2 stimulation), studies under hypoka-
laemic conditions (Fig. 1) revealed arrhythmogenicity at the
longest (A, five out of five hearts subjected to regular
stimulation, seven out of seven hearts subjected to S2
stimulation) but not the shortest (B, 0 out of five hearts
subjected to regular stimulation, one out of nine hearts
subjected to S2 stimulation) BCL studied. These results
correlated with clinical observations associating hypokalae-
mia with arrhythmogenicity.
Fig. 1 Arrhythmic activity in hypokalemic hearts. Epicardial mono-
phasic action potential recordings obtained during regular stimulation
(left) and following the application of extrasystolic (S2) stimuli at
S1S2 intervals just greater than the ventricular effective refractory
period (right) in hypokalemic (3.0 mM K
+) hearts paced at baseline
cycle lengths of 180 ms (a) and 80 ms (b). Single vertical lines
indicate the timing of S1 stimuli and double lines indicate the timing
of S2 stimuli
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decreases with decreasing baseline cycle length
Arrhythmogenicity was then studied over a range of BCLs
using the S2 stimulation protocol. Table 1 demonstrates a
graded dependence of the incidence of arrhythmic activity
upon BCL through the entire range of BCLs studied. The
experiments then went on to confirm the clinically
established antiarrhythmic effect of lidocaine under these
experimental conditions [10, 34, 45] over all BCLs. Thus,
S2 stimulation failed to initiate arrhythmic activity at any
BCL in either normokalaemic or hypokalaemic hearts
exposed to lidocaine (seven and six hearts at each BCL,
respectively).
Action potential duration and refractory period vary
with baseline cycle length
The subsequent experiments made systematic measure-
ments of action potential shapes, as represented in their
durations at 90% repolarization (APD90s), and VERPs
through the entire range of BCLs, thereby extending
previous experiments restricted to a single BCL [37].
Figure 2 displays the resulting findings, showing APD90s
(open symbols) and VERPs (filled symbols) obtained from
both the epicardium (circles) and the endocardium
(squares).
Thus Fig. 2a and b show that in normokalaemic hearts
both epicardial and endocardial APD90 varied with BCL,
decreasing from 51.2±1.7 and 60.6±6.0 ms, respectively, at
a BCL of 180 ms to 31.7±2.0 and 31.7±1.8 ms, respec-
tively, at a BCL of 80 ms (n=12; seven hearts). VERP
showed a similar trend, decreasing from 53±6 and 57±
1 ms, respectively at a BCL of 180 ms to 32±2 and 26±
1 ms, respectively, at a BCL of 80 ms (n=9; seven hearts).
In hypokalaemic hearts, both epicardial and endocardi-
al APD90 again varied with BCL, decreasing from 71.4±
6.2 and 60.1±6.3 ms, respectively, at a BCL of 180 ms to
37.3±3.5 and 36.0±3.5 ms, respectively, at a BCL of
80 ms (n=11; seven hearts; Fig. 2c,d). Compared to
normokalaemic hearts, VERP was significantly decreased
at all BCLs (P<0.01). However, VERP did not vary
significantly (P>0.05) with BCL (n=8; seven hearts).
In normokalaemic hearts treated with lidocaine both
epicardial and endocardial APD90 continued to vary with
BCL, decreasing from 59.5±4.2 and 56.1±8.1 ms, respec-
tively, at a BCL of 180 ms to 32.4±2.2 and 28.7±2.4 ms,
respectively, at a BCL of 80 ms (n=12; seven hearts;
Fig. 2e,f). As compared to normokalaemic hearts VERP
was significantly increased at all BCLs (P<0.01). However,
VERP did not vary significantly (P>0.05) with BCL (n=
12; seven hearts).
In hypokalaemic hearts treated with lidocaine both
epicardial and endocardial APD90 again varied with BCL,
decreasing from 59.2±3.4 and 87.7±2.6 ms, respectively, at
a BCL of 180 ms to 32.2±2.3 and 29.6±2.1 ms, respec-
tively, at a BCL of 80 ms (n=9; six hearts; Fig. 2g,h).
Compared to normokalaemic hearts, VERP was signifi-
cantly increased at all BCLs (P<0.05). VERP also
decreased with decreasing BCL from 65±4 and 62±8 ms,
respectively, at a BCL of 180 ms to 45±2 and 42±5 ms,
respectively, at a BCL of 80 ms (n=8; seven hearts).
Graphical analysis of arrhythmogenic tendency
The above data permitted an extension of a previous
analysis of arrhythmogenicity obtained in murine hearts
studied under similar conditions of hypokalaemia and
exposure to lidocaine but then confined to a single BCL
[37]. That earlier study successfully analysed arrhythmic
propensity in terms of possible reexcitation dependent on
the relative time courses of the recoveries of membrane
voltage and of excitability from total refractoriness to a
finite threshold for excitation following action potential
depolarization. This could involve either local myocardial
regions or, as suggested for congenital long QT syndrome
type 3, transmural interactions through the thickness of the
myocardial wall [25, 27, 44, 51].
Figures 3 and 4 thus represent equivalent parameters of
epicardial (circles) and endocardial (squares) APD90 plotted
against VERP in a graphical form for all BCLs studied for
all four test solutions (a–h, respectively). These provide
possible criteria for local (Fig. 3) and transmural (Fig. 4)
reexcitation as in the previous study. In Fig. 4, APD90s are
corrected for the time taken for depolarization to propagate
from endocardium to epicardium, given by the difference in
the latencies between stimulation and endocardial depolari-
zation and between stimulation and epicardial depolariza-
Table 1 Incidences of arrhythmic activity in hypokalaemic hearts
subjected to extrasystolic stimulation at a range of baseline cycle
lengths
Baseline cycle length (ms) Percent arrhythmic Number of hearts
180 100 7
160 86 6
140 71 5
120 22 9
100 11 9
80 11 9
Percentage of hypokalaemic (3.0 mM K
+) hearts demonstrating
arrhythmic activity following application of extrasystolic (S2) stimuli
at S1S2 intervals just greater than the ventricular effective refractory
period during pacing at baseline cycle lengths of 180, 160, 140, 120,
100 and 80 ms.
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normokalaemic hearts showed similar local and transmural
relationships whether obtained from the epicardium or
endocardium.
All these above relationships were linear. Thus, fits to the
linear function y=mx+c, where m denotes the constant
gradient and c the intercept with the ordinate, gave r
2
values of 0.98, 0.99, 0.99 and 0.98, respectively (P<<0.01
in all cases) and corresponding reduced χ
2 values of 8.13,
5.14, 5.22 and 1.15, respectively. However, the values of c
were statistically indistinguishable from zero (P>0.05) in
all cases (4.79±4.31, 4.54±1.32, 2.85±1.32 and 9.87±
3.56, respectively) and exclusion of this constant term did
not result in a significantly worse fit. Thus, repeating a
regression analysis this time fitting the line y=mx gave
indistinguishable regression values (with P<<0.01) and
gave a second set of reduced χ
2 values (10.2, 6.3, 6.5 and
1.3, respectively). This permitted the derivation of an F
statistic for the appropriate, N+1=6 data points given by
F ¼ N
χ2
1 χ2
2
χ2
2

in which the subscripts on the right hand
Fig. 2 Effect of baseline cycle
length on action potential dura-
tion and ventricular effective
refractory period. Relationship
between epicardial (circles) and
endocardial (squares) action po-
tential duration (at 90% repolar-
ization, APD90, open symbols),
ventricular effective refractory
period (VERP, filled symbols)
and cycle length in hearts ex-
posed to normokalaemic
(5.2 mM K
+; a, b) and hypo-
kalaemic (3.0 mM K
+; c, d) test
solutions, and normokalaemic
(e, f) and hypokalaemic (g, h)
test solutions containing
lidocaine (10 μM)
Pflugers Arch - Eur J Physiol (2007) 454:925–936 929side of the equation denote the number of parameters
involved [3]. This yielded P values of > 0.25 in all cases,
suggesting that the two fits were statistically indistinguish-
able and justifying adoption of the simpler function.
Taken together, statistical analysis of these data therefore
confirmed a linear relationship uniquely involving the
parameters of APD90 (corrected if appropriate) and VERP,
generalising the analysis presented by Sabir et al. [37] for a
single BCL to all BCLs. Furthermore, the resulting values
of m were matched to and indistinguishable from each other
and from unity in all, epicardial and endocardial, local and
transmural, cases (P>0.05). This permitted description of
the relationship between APD90 and VERP in terms of m,
or in terms of a critical angle, θ obtained by fitting the line
y ¼ x   tanq to the data points. Thus, in the latter analysis in
normokalaemic (5.2 mM K
+) hearts θ took statistically
indistinguishable (P>0.05) values of 45.8±0.9°, 46.6±0.5°,
47.6±0.5° and 44.9±0.8° in the four cases, respectively.
Fig. 3 Local relationships be-
tween epicardial and endocardial
action potential duration and
ventricular effective refractory
period obtained over a range of
baseline cycle lengths. Local
relationships between epicardial
(circles) and endocardial
(squares) action potential dura-
tion (at 90% repolarization,
APD
90) and ventricular effective
refractory period (VERP) in
hearts exposed to normokalae-
mic (5.2 mM K
+; a, b) and
hypokalaemic (3.0 mM K
+; c, d)
test solutions, and normokalae-
mic (e, f) and hypokalaemic
(g, h) test solutions containing
lidocaine (10 μM) and stimu-
lated at baseline cycle lengths of
between 80 ms and 180 ms.
Filled symbols indicate condi-
tions resulting in arrhythmic
activity in >50% of hearts
930 Pflugers Arch - Eur J Physiol (2007) 454:925–936The proarrhythmic effect of hypokalemia corresponds
to increases in the critical angle, θ, while the antiarrhythmic
effect of lidocaine-exposure corresponds to decreases in θ
Data points obtained through each experimental condition
could then be compared with these normokalaemic refer-
ence lines. Hypokalaemic situations where arrhythmogen-
esis was observed corresponded to points falling to the left
of these lines (Figs. 3 and 4). In contrast where arrhythmo-
genesis was prevented by the addition of lidocaine points
fell to the right of the reference lines. These geometrical
relationships were quantified using a simple approach that
obtained the angle subtended by each data point and the
abscissa at the origin. This provided a graphical expression
of a simple quotient:
q ¼ arctan
APD90
VERP

correcting for Δlatency where appropriate. This value was
then compared with the corresponding angle shown by the
Fig. 4 Transmural relationships
between action potential dura-
tion and ventricular effective
refractory period allowing for
transmural conduction time
obtained over a range of base-
line cycle lengths. Transmural
relationships between epicardial
(circles) and endocardial
(squares) action potential dura-
tion (at 90% repolarization,
APD90) plus transmural con-
duction time (Δlatency) and
ventricular effective refractory
period (VERP) in hearts ex-
posed to normokalaemic
(5.2 mM K
+; a, b) and hypo-
kalaemic (3.0 mM K
+; c, d) test
solutions, and normokalaemic
(e, f) and hypokalaemic (g, h)
test solutions containing lido-
caine (10 μM) and stimulated at
baseline cycle lengths of
between 80 ms and 180 ms.
Filled symbols indicate condi-
tions resulting in arrhythmic
activity in >50% of hearts
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reflected the requirement that any function relating the
necessarily positive values of APD90 to VERP would
traverse the origin: a zero APD90 i.e. no action potential
would correspond to a zero VERP. Thus, values of θ greater
or less than that of the reference lines would suggest pro-
and antiarrhythmic situations, respectively. Furthermore,
the extent to which θ remains constant as BCL varies would
provide an indication of the extent to which the relationship
between APD90 and VERP is maintained under any given
experimental condition. The analysis that follows explores
the extent to which such an analysis provides results that
correlate with observed arrhythmogenicity.
Figures 3c,d and 4c,d show that exposure of hearts to
hypokalaemic test solution indeed resulted in significant
increases in local and transmural θ values (P>0.05) in
relation to the reference values at all BCLs studied. All
hypokalaemic (3.0 mM) hearts gave points that lay to the
left of the reference line, corresponding to θ values of
greater than 45°. Those that did not demonstrate arrhythmic
activity (during pacing at BCLs between 80 and 120 ms,
open symbols) gave points that lay closer to the reference
line than those that were arrhythmogenic (paced at BCLs of
between 120 and 180 ms, filled symbols). In the first case,
the mean local θ values were ∼63° in epicardium (Fig. 3c)
and ∼54° in the endocardium (Fig. 3d), while the
corresponding transmural values were ∼55° (Fig. 4c) and
∼58° (Fig. 4d), respectively. In the second case the
corresponding values were ∼68° (Fig. 3c), ∼60° (Fig. 3d),
∼61° (Fig. 4c) and ∼65° (Fig. 4d).
Exposure of normokalaemic hearts to lidocaine signifi-
cantly reduced (P<0.05) mean local and transmural θ
values in relation to the reference values at all BCLs
studied. Thus, mean local θ values were ∼40° in the
epicardium (Fig. 3e) and ∼33° in the endocardium (Fig. 3f),
while the corresponding transmural values were ∼39°
(Fig. 4e) and ∼41° (Fig. 4f), respectively. Exposure of
hypokalaemic hearts to lidocaine again significantly re-
duced (P<0.05) mean local and transmural θ values in
relation to the reference values at all BCLs, accompanying
its antiarrhythmic effect as described above. Thus, local
mean local θ values were ∼40° in the epicardium (Fig. 3g)
and ∼44° in the endocardium (Fig. 3h), while
corresponding transmural values were ∼50° (Fig. 4g) and
∼48° (Fig. 4h), respectively.
Hypokalaemia alters the relationship between epicardial
and endocardial action potential durations
These findings were then compared with the results of an
extension of a previous analysis [17, 52], which involved
the comparison of endocardial and epicardial action
potential durations. This had proved successful in the
assessment of arrhythmogenicity in a murine model of the
congenital long QT syndrome type 3 (LQT3) [52], a
situation in which APD90 and VERP might be expected
always to vary concordantly, and in a murine model of
hypokalemia [17] at a single BCL. The present study
extends use of this analysis from a single BCL to a range of
BCLs, plotting endocardial APD90 on the abscissa and
epicardial APD90 on the ordinate over the range of BCLs
under the four above conditions (Fig. 5a–d). Filled symbols
indicate conditions under which arrhythmic activity was
observed in more than 50% of hearts.
In contrast to the previous analysis, the normokalaemic
plot (Fig. 5a) did not give a linear relationship between
endocardial and epicardial APD90s, but rather was fitted by
a quadratic function. Thus, the curve y ¼ ax2 þ bx þ c,
where a=−10.7±12.6, b=1.8±0.5 and c=−0.01±0.0 gave a
reduced χ
2 of 3.3, while fitting the line y=mx+c gave a
reduced χ
2 of 4.23, permitting calculation of an F statistic
for the appropriate, N+1=20 data points. This gave a
probability of exceeding F of <0.05, indicating that
inclusion of the quadratic term was statistically justified.
Hypokalaemia and lidocaine exposure resulted in loss of
the proportional relationship between (corrected) APD90
and VERP in all cases (Fig. 5b–d). While the departure of
points to the left of the reference curve under hypokalaemic
conditions were less marked than in the previous analysis, it
was nonetheless demonstrable (Fig. 5b). Exposure of both
normokalaemic (Fig. 5c) and hypokalaemic (Fig. 5d) hearts
to lidocaine gave points that were shifted towards more
positive endocardial APD90 values than seen in Fig. 5b.
Thus, in hypokalaemic hearts lidocaine displaced points to
the right, towards the reference curve (Fig. 5d), while in
normokalaemic hearts lidocaine displaced points to the left,
away from the reference curve (Fig. 5c). These observations
may be attributable to the disproportionate effect of
lidocaine on VERP as opposed to APD90.
Taken together these findings demonstrate that the
analysis of arrhythmogenicity in terms of the relative time
courses of recovery of membrane voltage and recovery of
excitability following depolarization presented by Sabir et
al. [37] for hypokalaemic conditions can be extended from
a single BCL to a range of BCLs. While a previous analysis
of arrhythmogenicity in terms of the relationship between
endocardial and epicardial action potential durations pro-
posed for LQT3 [52] and hypokalemia [17] successfully
predicted arrhythmogenicity, analyses incorporating VERP
proved more sensitive.
Discussion
The proarrhythmic effects of bradycardia and contrasting
antiarrhythmic effects of rapid pacing have been described
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associations are especially marked in the presence both of
congenital [43, 55] and of acquired (review in [28, 50])
electrocardiographic QT prolongation, of which clinical
hypokalaemia constitutes a common example. In the latter
situation, arrhythmogenesis is suppressed by treatment with
the class 1b antiarrhythmic agent lidocaine [10, 45]. The
present study sought to investigate the basis for these
phenomena using the intact murine heart as an experimental
model for arrhythmogenicity, as established on previous
occasions [2, 11, 12, 15, 17, 37, 47, 51, 52].
The murine heart is well established as a model for
human cardiac disease and importantly allows scope for the
introduction of genetic modifications [24]. Hence, it has
previously yielded important findings concerning mecha-
nisms underlying arrhythmogenicity in conditions including
the congenital long QT syndromes ([11, 12; see review in
[39, 47, 51, 52]), the Brugada syndrome [32, 46],
catecholaminergic polymorphic ventricular tachycardia [5,
23], cardiomyopathy [21] and hypokalemia [17, 37, 38].
Structurally, the sinoatrial node, atrioventricular node and
His-Purkinje system are similar in murine hearts and in the
hearts of larger mammals including humans [35], while
there are notable differences in size and in basal rate [53].
Nonetheless, murine and human ventricular action poten-
tials share rapid depolarization phases attributable to Na
+
currents [14], making the murine heart useful for studying
the effects of Na
+ channel blocking drugs such as lidocaine.
While differences in kinetics of the main currents respon-
sible for the repolarization phase (the transient outward
current, Ito, in mice and the delayed rectifier and slowly
inactivating delayed rectifier currents, IKr and IKs,i n
humans) result in the absence of a plateau phase and a
shorter ventricular action potential duration in mice [8]; all
such currents are K
+-sensitive [17, 31, 58], making the
murine heart suitable for the study of clinical hypokalae-
mia. Furthermore, murine and human hearts exhibit similar
spatial gradients in action potential duration [19], similar
relationships between action potential duration and refrac-
tory period [11, 20] and near identical transmural conduc-
tion velocities [16, 22], making murine hearts at the very
least suitable for the investigation of fundamental mecha-
nisms underlying arrhythmogenicity.
Thus, arrhythmogenicity was studied in hearts subjected
to a regular stimulation protocol and to an extrasystolic
stimulation protocol, previously used to assess arrhythmo-
genicity and refractoriness in both human [42] and murine
[15] studies of the congenital long QT syndromes, at a
range of baseline cycle lengths (BCLs). This represents the
first experimental exploration of the effect of BCL on
arrhythmogenicity under hypokalaemic conditions in any
species and of the effect of BCL on arrhythmogenicity in
the murine heart under any conditions. Under normokalae-
Fig. 5 Relationships between epicardial and endocardial action
potential durations (at 90% repolarization, APD90s) obtained over a
range of baseline cycle lengths. Hearts exposed to normokalaemic
(5.2 mM K
+; a) and hypokalaemic (3.0 mM K
+; b) test solutions, and
normokalaemic (c) and hypokalaemic (d) test solutions containing
lidocaine (10 μM) and stimulated at baseline cycle lengths of between
80 ms and 180 ms. Filled symbols indicate conditions resulting in
arrhythmic activity in >50% of hearts
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(MAPs) that consistently demonstrated stable waveforms
and rhythms during both protocols. We report for the first
time that hypokalaemic hearts demonstrated periods of both
transient and sustained arrhythmic activity when these
protocols were applied at long, but not short, BCLs.
Furthermore, arrhythmic activity was never observed
during treatment with lidocaine under either condition
during either protocol. Taken together, these findings thus
parallel the clinical observations.
The experiments accordingly extended the analysis of
arrhythmic propensity established by Sabir et al. [37] from
single BCL to a range of BCLs. As in that previous study,
the analysis that followed explored the tendency towards
reexcitation and arrhythmogenesis in terms of relative
changes in the time courses of the recovery of membrane
voltage and the recovery of excitability after depolarization.
It went on to describe propensity to reexcitation of both the
epicardium and the endocardium either arising locally or
from a transmural source using novel graphical representa-
tions. These plotted action potential durations (at 90%
repolarization, APD90s) obtained through the range of
BCLs explored against the corresponding ventricular
effective refractory periods (VERPs). In transmural plots,
APD90s were corrected for the time taken for depolarization
to propagate from endocardium to epicardium, given by the
difference in the latencies between stimulation and endo-
cardial depolarization and between stimulation and epicar-
dial depolarization (Δlatency).
A statistical analysis suggested that the relationships
between APD90 and VERP varied along linear functions in
normokalaemic hearts. Furthermore, the functions consis-
tently passed through the origin, excluding any necessity
for additional constant terms, and did so with gradients of
near unity. Together these findings extend previous results
from murine [19], canine [13], and human [20]s t u d i e s .
The various relationships between APD90 and VERP
could then be described by critical angles, θ unique to
each case for all BCLs. We demonstrate for the first time
that hypokalaemia disrupted these simple linear relation-
ships and additionally significantly increased all values of
θ at all BCLs. Furthermore, the largest values of θ were
observed in hearts paced at the longest BCLs (140–
180 ms), which were in turn associated with the highest
incidences of arrhythmic activity. Treatment of both
normokalaemic and hypokalaemic hearts with lidocaine
resulted in significantly lower θ values than were obtained
in the absence of the drug, again at all BCLs. This
paralleled its antiarrhythmic effect in hypokalaemic hearts.
However, under normokalaemic conditions, lidocaine
abolished the directly proportional relationship between
APD90 and VERP and could thereby exert a rate-limiting
effect in vivo at short BCLs.
In summary, using an experimental model we success-
fully replicated the clinical effects of BCL on arrhythmo-
genicity and in particular the association between
bradycardia and arrhythmogenesis [1, 10, 28, 33, 43, 45,
49, 50, 55]. This led to the development of criteria
predictive of such arrhythmogenicity that compared local
and transmural, epicardial and endocardial relationships
between APD90 and VERP. Such an approach agrees with
and extends previous criteria for arrhythmogenicity invok-
ing transmural repolarization gradients expressed through
the relationship between epicardial and endocardial APD90
values [17, 51]. Such criteria have been shown to predict
arrhythmogenicity in murine models of the congenital long
QT syndrome type 3 (LQT3) [51] and of hypokalemia [17,
38]. However, these studies were restricted to a single BCL.
Furthermore, LQT3 results from a Na
+ channel mutation
and therefore produces proportionate prolongations of
APD90 and VERP [51]. Hence, in LQT3 the transmural
relationships between APD90 and VERP would be expected
to be in direct agreement with the transmural differences
in action potential repolarization time. This contrasts with
situations illustrated in the present paper where APD90 and
VERP sharply diverge, particularly in the presence of
lidocaine.
Thus, the analyses presented in this study represent a
generalization of previous criteria, which is applicable over
a range of BCL and in situations where changes in APD90
and VERP occur independently. Thus, it would predict that
action potential prolongation should prove especially pro-
arrhythmic where APD90 is disproportionately prolonged as
compared to VERP. Such an interpretation would be
applicable in explaining the contrasting pro- or anti-
arrhythmic effects of various agents sharing apparently
similar effects on action potential waveforms. Thus, the
proarrhythmic effects of the anti-psychotic agents haloper-
idol [41] and sulpiride [48] and of the antibiotic agent
sparfloxacin [40] in canine models, which demonstrate
action potential characteristics almost identical to those in
humans, are associated with disproportionate increases
action potential duration as compared to VERP. Conversely,
the anti-arrhythmic effects of various class 1 agents
including lidocaine are associated with disproportionate
increases in VERP compared to action potential duration [7,
29], as reflected in this study. It would then directly follow
that procedures used to predict the proarrhythmic potential
of QT prolonging drugs and arrhythmic propensity in
patients exhibiting QT prolongation should incorporate
assessment of VERP and should be conducted at a range
of heart rates.
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